You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients

You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients.

This is based on a new meta-analysis that suggests gliptins don't increase cardiovascular risk...and MIGHT even decrease it.

But this analysis hasn't been peer-reviewed and published.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote